



May 13, 2020

**TO:** Healthcare Providers, Healthcare Facilities, Clinical Laboratories, and Local Health Departments  
**FROM:** New York State Department of Health (NYSDOH)

**HEALTH ADVISORY: PEDIATRIC MULTI-SYSTEM INFLAMMATORY SYNDROME TEMPORALLY ASSOCIATED WITH COVID-19 INTERIM CASE DEFINITION IN NEW YORK STATE**

**SUMMARY**

- Recently a possible link has been reported between COVID-19 and Pediatric Multi-System Inflammatory Syndrome (PMIS) temporally associated with COVID-19.
- As of May 12<sup>th</sup>, 102 suspect cases of PMIS have been reported by hospitals in New York State and are under investigation by the New York State Department of Health.
- Suspect and confirmed cases of PMIS potentially associated with COVID-19 in those under 21 years of age **are required to be reported** to the NYSDOH.
- The New York State Department of Health has established a preliminary case definition for PMIS based upon the review of cases to date.

**INTERIM CASE DEFINITION: PEDIATRIC MULTISYSTEM INFLAMMATORY SYNDROME TEMPORALLY ASSOCIATED WITH SARS-CoV-2**

**Clinical Criteria:** An individual aged < 21 years with:

- A minimum one-day history of subjective **OR** objective fever ( $\geq 100.4^{\circ}$  F/ $38^{\circ}$  C); **AND**
- Hospitalization; **AND**
- **Either:**
  - **One or more** of the following:
    - Hypotension or shock (cardiogenic or vasogenic)
    - Features of severe cardiac illness including but not limited to myocarditis, pericarditis, or valvulitis, significantly elevated troponin/pro-BNP, or coronary artery abnormalities
    - Other severe end-organ involvement including but not limited to neurological or renal disease (excluding severe respiratory disease alone)
  - OR**
  - **Two or more** of the following:
    - Maculopapular rash
    - Bilateral non-purulent conjunctivitis
    - Mucocutaneous inflammatory signs (mouth, hands, or feet)
    - Acute gastrointestinal symptoms (diarrhea, vomiting, or abdominal pain); **AND**
- The absence of a more likely diagnosis of the illness, e.g., bacterial sepsis or other viral infection.

### **Laboratory Criteria:**

- **General Laboratory Criteria:** Two or more of the following markers of inflammation:
  - Neutrophilia, lymphopenia, thrombocytopenia, hypoalbuminemia, elevated C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), fibrinogen, D-Dimer, ferritin, lactic acid dehydrogenase (LDH), interleukin 6 (IL-6), OR elevated procalcitonin
- **Virologic Laboratory Criteria:** One of the following SARS-CoV-2 laboratory results<sup>1</sup>
  - Detection of SARS-CoV-2 RNA in a clinical specimen using a molecular amplification detection test (e.g., RT-PCR) (or detection of SARS-CoV-2 antigen in a clinical specimen), at the time of presentation with this clinical picture or within the prior 4 weeks.
  - Detection of SARS-CoV-2 antibody in serum, plasma, or whole blood indicative of a new or recent infection.

### **Epidemiologic Criteria:**

One or more of the following exposures in the 6 weeks prior to the onset of symptoms:

- Close contact with an individual with laboratory-confirmed SARS-CoV-2 infection.<sup>1</sup>
- Close contact with an individual with illness clinically compatible with COVID-19 disease who had close contact with an individual with laboratory-confirmed SARS-CoV-2 infection.<sup>1</sup>
- Travel to or residence in an area with sustained, ongoing community transmission of SARS-CoV-2.

### **CASE CLASSIFICATIONS:**

*Confirmed:* Meets clinical, general laboratory, and virologic laboratory criteria

*Suspect:* Meets clinical, general laboratory, and epidemiologic criteria

### **REPORTING**

- Suspect and confirmed cases of pediatric multisystem inflammatory syndrome potentially associated with COVID-19 in those under 21 years of age must be reported to the NYSDOH.
- Hospitals are required to report pediatric multisystem inflammatory syndrome potentially associated with COVID-19 daily using the HERDS application on the NYSDOH health commerce system.
- In addition, clinicians are strongly encouraged to perform molecular testing for SARS-CoV-2 and serologic testing on all suspect cases.

*For questions about the HERDS survey: please send an e-mail to [hospinfo@health.ny.gov](mailto:hospinfo@health.ny.gov).*

*Providers who have questions can contact the NYSDOH Bureau of Communicable Disease Control at 518-473-4439 during business hours or 1-866-881-2809 evenings, weekends, and holidays.*

---

<sup>1</sup> Based on the use of an FDA authorized test